[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 9, 1948


Author Affiliations

New York

From the Departments of Ophthalmology and Bacteriology, College of Physicians and Surgeons, Columbia University, New York.

JAMA. 1948;138(6):426-427. doi:10.1001/jama.1948.62900060015009

In recent months, a mold belonging to the Streptomyces group has been isolated by workers1 at the Lederle Laboratories, American Cyanamid Company. The antibiotic derived from this mold has been named "aureomycin," and numerous tests against gram-positive as well as against gram-negative organisms have strongly suggested that it might have an unusual degree of potency and range of activity. On the basis of information regarding the fundamental investigations2 which the Lederle Laboratories provided us, it seemed desirable to test aureomycin in patients suffering with external diseases of the eye.

This new antibiotic has been used in 100 cases of ocular disease. For the most part, aureomycin was administered locally as a 0.5 per cent solution of a borate salt having a pH of 7.5 to 7.8 when dissolved in isotonic sodium chloride solution. The 0.5 per cent solution of the antibiotic was only mildly irritating to the